Inotropic Agents Market

Inotropic Agents Market (Type: Positive Inotropic Agents and Negative Inotropic Agents; and Route of Administration: Oral, Parenteral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Global Inotropic Agents Market Outlook 2031

  • The global industry was valued at US$ 1.9 Bn in 2022
  • It is projected to advance at a CAGR of 11.4% from 2023 to 2031 and reach more than US$ 5.1 Bn by the end of 2031

Analysts’ Viewpoint on Market Scenario

The global market for inotropic agents is expected to grow at a rapid pace in the near future due to various factors such as increase in the geriatric population, rise in the incidence of heart failure, and expansion in the healthcare sector. Technological advancements in drug development and delivery methods are also augmenting the inotropic agents market development.

However, industry growth is likely to be hindered by factors such as high cost of inotropic agents, limited product pipeline, and the availability of alternative treatments. Key players in the industry are investing in R&D to improve the efficacy and safety of inotropic agents and to develop new, more advanced products.

Inotropic Agents Market

Market Introduction

Inotropic agents are drugs that are used for the treatment of heart failure and other cardiac conditions. They alter the ionic concentration of the heart muscles, which in turn, affects the flow of calcium ions into the cells. This leads to an increase or decrease in the strength and rate of the heart's contractions, depending on the type of inotropic agent employed.

Rise in Incidence of Heart Failure Driving Inotropic Agents Market Development

Heart failure is a condition in which the heart cannot pump enough blood to meet the body's demands, leading to fatigue, shortness of breath, and fluid accumulation in the legs and ankles. Inotropic agents improve the force of contraction of the heart muscle. Thus, surge in the prevalence of cardiovascular diseases is projected to spur the inotropic agents market growth in the near future. Rise in the geriatric population and increase in adoption of unhealthy lifestyles are also likely to boost the demand for inotropic agents in the near future.

Surge in Awareness Regarding Heart Failure and its Treatment Options

Inotropic agents play a crucial role in the management of heart failure. Awareness about the importance of inotropic agents is growing among healthcare providers and patients in improving the symptoms and quality of life of patients with heart failure. This is estimated to propel the inotropic agents market size in the next few years. Additionally, government initiatives to increase awareness about heart failure, improve access to healthcare, and support research and development in the field are also contributing to the high demand for inotropic agents.

Positive Inotropic Agents Gaining Traction

The positive inotropic agents type segment is projected to hold major share during the forecast period, as per the latest inotropic agents industry report. Positive inotropic agents help increase the strength of heart contractions. This makes them an effective treatment option for heart failure and other conditions that lead to weak heart muscles. Positive inotropic agents are the most commonly used type of inotropic agents and are prescribed to help improve the heart's ability to pump blood.

Extensive Usage of Inotropic Agents for Heart Failure and Cardiogenic Shock Treatment

According to the latest inotropic agents market analysis, the heart failure and cardiogenic shock indication segment is estimated to dominate the industry from 2023 to 2031. Heart failure and cardiogenic shock are characterized by the inability of the heart to pump enough blood to meet the body's needs. Inotropic agents are employed to enhance the contractility of the heart muscle and increase blood flow, thereby improving the symptoms of heart failure and cardiogenic shock.

High Rate of Adoption of Parenteral Route of Administration

According to the latest inotropic agents market trends, the parenteral route of administration segment is expected to hold largest share during the forecast period. Inotropic agents are often administered via the parenteral route, as it allows for rapid and direct delivery of drugs to the heart. This is especially important in emergency situations, such as cardiogenic shock, where rapid treatment is critical. In these cases, the parenteral administration of inotropic agents can help restore blood flow to the body's vital organs and improve the heart's ability to pump blood.

Regional Outlook of Inotropic Agents Market

North America is projected to dominate the industry from 2023 to 2031. High prevalence of heart failure and other cardiac conditions, rise in the geriatric population, and the presence of a large number of pharmaceutical companies and research institutions are boosting market expansion in the region. The U.S. is a major growth engine of the industry in North America.

The market in Asia Pacific is estimated to grow at a rapid pace during the forecast period. The healthcare sector is expanding rapidly in the region due to surge in government expenditure on the healthcare sector. China and India are major growth engines of the industry in Asia Pacific. Rise in demand for advanced healthcare technologies is also propelling market statistics in the region.

Analysis of Key Players

The global market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent inotropic agents market developments. Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, and Cipla Inc. are major entities operating in this industry.

Manufacturers are forming partnerships with other companies, academic institutions, and research organizations to increase their inotropic agents market share. They are also focused on accelerating the development of new products, improving their distribution channels, and gaining access to new markets.

Key Developments

  • In October 2022, Windtree Therapeutics, Inc., a biotechnology company, received a patent for istaroxime administration in the U.S. Istaroxime has a novel dual mechanism of action that increases both systolic contraction and diastolic relaxation.
  • In October 2021, Hyloris Pharmaceuticals SA, a specialty biopharma company, acquired the global rights to CRD-102 (and related intellectual property), a novel, clinical-stage, extended-release Milrinone capsule in late-stage heart failure (HF) patients with an implanted left ventricular assist device who have developed right HF, from the Baker Heart and Diabetes Institute, Australia

Inotropic Agents Market Snapshot

Attribute

Detail

Market Size Value in 2022

US$ 1.9 Bn

Market Forecast Value in 2031

More than US$ 5.1 Bn

Growth Rate (CAGR)

11.4%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Positive Inotropic Agents
    • Negative Inotropic Agents
  • Indication
    • Heart Attack
    • Heart Failure and Cardiogenic Shock
    • Angina
    • Arrhythmia
    • Others
  • Route of Administration
    • Oral
    • Parenteral
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Mylan N.V.
  • Boehringer Ingelheim International GmbH
  • AstraZeneca
  • Johnson & Johnson
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global inotropic agents market in 2022?

The global market was valued at US$ 1.9 Bn in 2022

How big will the industry be in 2031?

It is projected to reach more than US$ 5.1 Bn by the end of 2031

What will be the CAGR during the forecast period?

It is anticipated to be 11.4% from 2023 to 2031

Which are the prominent trends that affect business growth?

Rise in incidence of heart failure and increase in awareness about heart failure and its treatment options

Which region will account for major share during the forecast period?

North America is projected to account for major share from 2023 to 2031

Who are the prominent players operating in the market?

Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, and Cipla Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Inotropic Agents Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Inotropic Agents Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Insights on Short-term Treatments For Acute Cardiac Care

    5.2. Disease Prevalence & Incidence Rate Globally with Key Countries

    5.3. Regulatory Scenario by Region/Globally

    5.4. COVID-19 Impact Analysis

6. Global Inotropic Agents Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Type, 2017–2031

        6.3.1. Positive Inotropic Agents

        6.3.2. Negative Inotropic Agents

    6.4. Market Attractiveness Analysis, by Type

7. Global Inotropic Agents Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Indication, 2017–2031

        7.3.1. Heart Attack

        7.3.2. Heart Failure and Cardiogenic Shock

        7.3.3. Angina

        7.3.4. Arrhythmia

        7.3.5. Others

    7.4. Market Attractiveness Analysis, by Indication

8. Global Inotropic Agents Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Route of Administration, 2017–2031

        8.3.1. Oral

        8.3.2. Parenteral

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Inotropic Agents Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017–2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Inotropic Agents Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017–2031

        10.2.1. Positive Inotropic Agents

        10.2.2. Negative Inotropic Agents

    10.3. Market Value Forecast, by Indication, 2017–2031

        10.3.1. Heart Attack

        10.3.2. Heart Failure and Cardiogenic Shock

        10.3.3. Angina

        10.3.4. Arrhythmia

        10.3.5. Others

    10.4. Market Value Forecast, by Route of Administration, 2017–2031

        10.4.1. Oral

        10.4.2. Parenteral

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Indication

        10.6.3. By Route of Administration

        10.6.4. By Country

11. Europe Inotropic Agents Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017–2031

        11.2.1. Positive Inotropic Agents

        11.2.2. Negative Inotropic Agents

    11.3. Market Value Forecast, by Indication, 2017–2031

        11.3.1. Heart Attack

        11.3.2. Heart Failure and Cardiogenic Shock

        11.3.3. Angina

        11.3.4. Arrhythmia

        11.3.5. Others

    11.4. Market Value Forecast, by Route of Administration, 2017–2031

        11.4.1. Oral

        11.4.2. Parenteral

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Indication

        11.6.3. By Route of Administration

        11.6.4. By Country/Sub-region

12. Asia Pacific Inotropic Agents Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017–2031

        12.2.1. Positive Inotropic Agents

        12.2.2. Negative Inotropic Agents

    12.3. Market Value Forecast, by Indication, 2017–2031

        12.3.1. Heart Attack

        12.3.2. Heart Failure and Cardiogenic Shock

        12.3.3. Angina

        12.3.4. Arrhythmia

        12.3.5. Others

    12.4. Market Value Forecast, by Route of Administration, 2017–2031

        12.4.1. Oral

        12.4.2. Parenteral

        12.4.3. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Indication

        12.6.3. By Route of Administration

        12.6.4. By Country/Sub-region

13. Latin America Inotropic Agents Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017–2031

        13.2.1. Positive Inotropic Agents

        13.2.2. Negative Inotropic Agents

    13.3. Market Value Forecast, by Indication, 2017–2031

        13.3.1. Heart Attack

        13.3.2. Heart Failure and Cardiogenic Shock

        13.3.3. Angina

        13.3.4. Arrhythmia

        13.3.5. Others

    13.4. Market Value Forecast, by Route of Administration, 2017–2031

        13.4.1. Oral

        13.4.2. Parenteral

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Indication

        13.6.3. By Route of Administration

        13.6.4. By Country/Sub-region

14. Middle East & Africa Inotropic Agents Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Type, 2017–2031

        14.2.1. Positive Inotropic Agents

        14.2.2. Negative Inotropic Agents

    14.3. Market Value Forecast, by Indication, 2017–2031

        14.3.1. Heart Attack

        14.3.2. Heart Failure and Cardiogenic Shock

        14.3.3. Angina

        14.3.4. Arrhythmia

        14.3.5. Others

    14.4. Market Value Forecast, by Route of Administration, 2017–2031

        14.4.1. Oral

        14.4.2. Parenteral

        14.4.3. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Indication

        14.6.3. By Route of Administration

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis, by Company (2022)

    15.3. Company Profiles

        15.3.1. Pfizer Inc.

            15.3.1.1. Company Overview

            15.3.1.2. Type Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. GSK plc

            15.3.2.1. Company Overview

            15.3.2.2. Type Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Novartis AG

            15.3.3.1. Company Overview

            15.3.3.2. Type Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Mylan N.V.

            15.3.4.1. Company Overview

            15.3.4.2. Type Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Boehringer Ingelheim International GmbH

            15.3.5.1. Company Overview

            15.3.5.2. Type Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. AstraZeneca

            15.3.6.1. Company Overview

            15.3.6.2. Type Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. Johnson & Johnson

            15.3.7.1. Company Overview

            15.3.7.2. Type Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Bayer AG

            15.3.8.1. Company Overview

            15.3.8.2. Type Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Merck & Co., Inc.

            15.3.9.1. Company Overview

            15.3.9.2. Type Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. Bristol-Myers Squibb Company

            15.3.10.1. Company Overview

            15.3.10.2. Type Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

        15.3.11. Cipla Inc.

            15.3.11.1. Company Overview

            15.3.11.2. Type Portfolio

            15.3.11.3. SWOT Analysis

            15.3.11.4. Financial Overview

            15.3.11.5. Strategic Overview

        15.3.12. Other Prominent Players

            15.3.12.1. Company Overview

            15.3.12.2. Type Portfolio

            15.3.12.3. SWOT Analysis

            15.3.12.4. Financial Overview

            15.3.12.5. Strategic Overview

List of Tables

Table 01: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 02: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 03: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 07: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 09: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 11: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 13: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 15: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 17: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 19: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 21: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 23: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

List of Figures

Figure 01: Global Inotropic Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global Inotropic Agents Market Revenue (US$ Mn), by Type, 2022

Figure 03: Global Inotropic Agents Market Value Share, by Type, 2022

Figure 04: Global Inotropic Agents Market Revenue (US$ Mn), by Indication, 2022

Figure 05: Global Inotropic Agents Market Value Share, by Indication, 2022

Figure 06: Global Inotropic Agents Market Revenue (US$ Mn), by Route of Administration, 2022

Figure 07: Global Inotropic Agents Market Value Share, by Route of Administration, 2022

Figure 08: Global Inotropic Agents Market Value Share, by Region, 2022

Figure 09: Global Inotropic Agents Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031

Figure 11: Global Inotropic Agents Market Attractiveness Analysis, by Type, 2022-2031

Figure 12: Global Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 13: Global Inotropic Agents Market Attractiveness Analysis, by Indication, 2022-2031

Figure 14: Global Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 15: Global Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2022-2031

Figure 16: Global Inotropic Agents Market Value Share Analysis, by Region, 2022 and 2031

Figure 17: Global Inotropic Agents Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Inotropic Agents Market Attractiveness Analysis, by Country, 2017–2031

Figure 20: North America Inotropic Agents Market Value Share Analysis, by Country, 2022 and 2031

Figure 21: North America Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031

Figure 22: North America Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 23: North America Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 24: North America Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031

Figure 25: North America Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 26:North America Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 27: Europe Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 29: Europe Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031

Figure 31: Europe Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 32: Europe Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 33: Europe Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031

Figure 34: Europe Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 35: Europe Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 36: Asia Pacific Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 38: Asia Pacific Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 39: Asia Pacific Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031

Figure 40: Asia Pacific Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 41: Asia Pacific Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 42: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031

Figure 43: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 44: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 45: Latin America Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 47: Latin America Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 48: Latin America Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031

Figure 49: Latin America Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 50: Latin America Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 51: Latin America Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031

Figure 52: Latin America Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 53: Latin America Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 54: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 56: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 57: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031

Figure 58: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 59: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 60: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031

Figure 61: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 62: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved